SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio’s lead biologic product (Anktiva), wh ...

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 Mar 27, 2026 8:15 AM Eastern Daylight Time Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 Share Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit,† ...

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access Mar 26, 2026 4:52 PM Eastern Daylight Time Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access Share Webcast on Tuesday, March 31, 2026, at 4:30 p.m. ET LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc.("Agenus†) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will ...

An updated edition of the February 5, 2026, article.The global oncology market is entering a period of rapid evolution, fueled by rising cancer incidence, aging populations and continued scientific breakthroughs. According to the American Cancer Society, the United States alone is projected to record approximately 2.1 million new cancer cases and more than 626,000 deaths in 2026. On a global scale, increasing exposure to lifestyle-related risk factors—such as smoking, obesity, and sedentary behavior— and de ...

Innate Pharma Reports Full Year 2025 Financial Results and Business Update Mar 26, 2026 2:00 AM Eastern Daylight Time Innate Pharma Reports Full Year 2025 Financial Results and Business Update Share MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate†or the "Company†) today reported its business update and consolidated financial results for the year ending December 31, 2025. The consolidated financial statements are attached to this press rele ...

Tivic Health Systems (NasdaqCM:TIVC) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Company ParticipantsLisa Wolf - CFOMichael Handley - CEOOperatorWelcome to Tivic's conference call to discuss fiscal year and fourth quarter 2025 financial results. This call has been pre-recorded. This call is being webcast, and the replay will be available on the IR section of the company's website for three months. Before we begin, please note that during today's call, management will make various forward-looking statem ...

Tivic Health Systems (NasdaqCM:TIVC) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Company ParticipantsLisa Wolf - CFOMichael Handley - CEOOperatorWelcome to Tivic's conference call to discuss fiscal year and fourth quarter 2025 financial results. This call has been pre-recorded. This call is being webcast, and the replay will be available on the IR section of the company's website for three months. Before we begin, please note that during today's call, management will make various forward-looking statem ...

Precigen (NasdaqGS:PGEN) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Speaker5This call is being recorded on Wednesday, March 25, 2026. I would now like to turn the conference over to Steven Harasym. Please go ahead.Speaker8Thank you, operator, and thank you to all those joining us for our fourth quarter and year-end 2025 update call. Joining me today are Helen Sabzevari, our President and CEO, Phil Tennant, our Chief Commercial Officer, and Harry Thomasian Jr., our CFO. Before we begin our prepared rem ...

Tivic Health Systems (NasdaqCM:TIVC) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Speaker2Welcome to Tivic's conference call to discuss fiscal year and fourth quarter 2025 financial results. This call has been pre-recorded. This call is being webcast, and the replay will be available on the IR section of the company's website for three months. Before we begin, please note that during today's call, management will make various forward-looking statements. Investors are cautioned that these forward-looking ...

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasd ...